Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; University Department of Psychiatry and Mental Health, University of Cape TownCape Town, South Africa; University Guangji Hospital, Suzhou, China; University Department of Psychiatry, Academic Centre, College Keep, 4-12 Terminus Terrace, Southampton, United Kingdom
Baldwin, D.S., Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom, University Department of Psychiatry and Mental Health, University of Cape TownCape Town, South Africa, University Guangji Hospital, Suzhou, China, University Department of Psychiatry, Academic Centre, College Keep, 4-12 Terminus Terrace, Southampton, United Kingdom; Manson, C., Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Nowak, M., Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
Pleasurable sexual activity is important in many human relationships and can provide a sense of physical, emotional and social well-being. Depressive symptoms and depressive illness are associated with impairments in sexual function and sexual dissatisfaction in untreated and treated patients. Most currently available antidepressant drugs are associated with development or worsening of sexual dysfunction in a substantial proportion of patients. Sexual difficulties during antidepressant treatment often resolve as depression lifts, but can persist over long periods, reducing self-esteem and affecting mood and relationships adversely. Sexual difficulties during antidepressant treatment typically have many possible causes but the incidence and nature of dysfunction varies between drugs. Many interventions can be considered when managing sexual dysfunction associated with antidepressants but no approach is 'ideal'. Because treatment-emergent sexual difficulties are less frequent with certain drugs, presumably related to differences in pharmacological properties, and since current interventions are suboptimal, a lower incidence of sexual dysfunction is a relevant tolerability target when developing novel antidepressants. © 2015 Springer International Publishing Switzerland.
agomelatine; amfebutamone; amineptine; antidepressant agent; aripiprazole; clomipramine; dapoxetine; escitalopram; fluoxetine; fluvoxamine; lithium; mirtazapine; moclobemide; nefazodone; olanzapine; paroxetine; phosphodiesterase V inhibitor; placebo; serotonin noradrenalin reuptake inhibitor; serotonin uptake inhibitor; sertraline; sildenafil; tadalafil; testosterone; trazodone; unindexed drug; venlafaxine; vilazodone; vortioxetine; yohimbine; Article; clinical assessment; clinical trial (topic); depression; drug design; drug efficacy; drug induced headache; drug safety; drug tolerability; dyspepsia; functional magnetic resonance imaging; human; incidence; major depression; mental patient; priority journal; prospective study; psychopharmacotherapy; randomized controlled trial (topic); sexual behavior; sexual dysfunction; sexual function; sexual satisfaction; treatment outcome; treatment response; visual disorder